Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
05 Mars 2024 - 7:30AM
UK Regulatory
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II
Clinical Trial of Neoantigen Cancer Vaccine TG4050
Strasbourg (France), Tokyo (Japan) and
Waltham, Mass (USA), March 5th, 2024, 7:30 am
CET - Transgene (Euronext Paris: TNG), a biotech company
that designs and develops virus-based immunotherapies for the
treatment of cancer, NEC Corporation (NEC; TSE: 6701), a leader in
IT, network and AI technologies and BostonGene Corporation
(BostonGene), a leading company in AI-based molecular and immune
profiling, today announced the expansion of their collaboration for
the randomized Phase I/II trial of TG4050, an individualized
therapeutic vaccine for patients with head and neck cancers.
BostonGene is partnering with NEC and Transgene
to continue performing tumor molecular profiling and
microenvironment analysis and provide high-throughput sequencing
services. The partnership with BostonGene will enable fast
turnaround of next-generation sequencing (NGS) data, and
sophisticated analytics will enable comprehensive profiling of
patient immune contexture.
TG4050, a personalized immunotherapy designed to
stimulate the immune system of patients to induce a neoantigen
specific T-cell response that can recognize and destroy tumor
cells, is based on Transgene’s myvac® platform and powered
by NEC’s AI-driven Neoantigen Prediction System.
“Our collaboration with BostonGene
has provided in-depth information on patient phenotypes in the
Phase I trial. It has allowed us to understand the baseline status
of our patients and how the tumor micro-environment (TME) might
evolve following treatment,” said Dr. Alessandro Riva,
Chairman and CEO of Transgene.
“The combined expertise of Transgene, NEC
and BostonGene will continue to provide a streamlined pipeline for
the timely delivery of patient-tailored vaccines as well as data to
guide the future development of new personalized treatment options,
elevating the standard of care for head and neck cancer
patients,” said Masamitsu Kitase, Corporate SVP and
Head of the Healthcare and Life Sciences Division at NEC
Corporation.
“We are committed to supporting Transgene
and NEC as they advance these clinical trials,”
said Nathan Fowler, MD, Chief Medical Officer at
BostonGene. “Our molecular and immune profiling
techniques comprehensively analyze the tumor, microenvironment, and
immune system to identify key predictors of response to TG4050,
ultimately improving treatment outcomes.”
About myvac®
myvac® is a viral vector (MVA – Modified Vaccinia
Ankara) based, individualized immunotherapy platform that has
been developed by Transgene to target solid tumors.
myvac®-derived products are designed to stimulate the
patient’s immune system to recognize and destroy tumors using their
own cancer specific genetic mutations. Transgene has set up an
innovative network that combines bioengineering, digital
transformation, established vectorization know-how and unique
manufacturing capabilities. Transgene has been awarded “Investment
for the Future” funding from Bpifrance for the development of its
platform myvac®. TG4050 is the first
myvac®-derived product being evaluated in clinical
trials.
Click here to watch a short video on
myvac®.
About TG4050
TG4050 is an individualized immunotherapy being developed for solid
tumors that is based on Transgene’s myvac® technology and
powered by NEC’s longstanding artificial intelligence (AI) and
machine learning (ML) expertise. This virus-based therapeutic
vaccine encodes neoantigens (patient-specific mutations) identified
and selected by NEC’s Neoantigen Prediction System. The prediction
system is based on more than two decades of expertise in AI and has
been trained on proprietary data allowing it to accurately
prioritize and select the most immunogenic sequences.
TG4050 is designed to stimulate the immune system of patients in
order to induce a T-cell response that is able to recognize and
destroy tumor cells based on their own neoantigens. This
individualized immunotherapy is developed and produced for each
patient.
Initial immunological and clinical data from the ongoing Phase I
trial in the adjuvant treatment of HPV-negative head and neck
cancers were presented at several conferences in 2023 and are very
encouraging.
About Transgene
Transgene (Euronext: TNG) is a biotechnology
company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells.
The Company’s clinical-stage programs consist of a portfolio of
therapeutic vaccines and oncolytic viruses:
TG4050, the first individualized therapeutic vaccine based on the
myvac® platform, TG4001 for the treatment of HPV-positive
cancers, as well as BT-001 and TG6050, two oncolytic viruses based
on the Invir.IO® viral backbone.
With Transgene’s myvac® platform, therapeutic vaccination
enters the field of precision medicine with a novel immunotherapy
that is fully tailored to each individual. The myvac®
approach allows the generation of a virus-based immunotherapy that
encodes patient-specific mutations identified and selected by
Artificial Intelligence capabilities provided by its partner
NEC.
With its proprietary platform Invir.IO®, Transgene is building on
its viral vector engineering expertise to design a new generation
of multifunctional oncolytic viruses.
Additional information about Transgene is available at:
www.transgene.fr
Follow us on social media: X (previously-Twitter): @TransgeneSA –
LinkedIn: @Transgene
About NEC
Corporation
NEC Corporation has established itself as a leader in the
integration of IT and network technologies while promoting the
brand statement of “Orchestrating a brighter world.” NEC enables
businesses and communities to adapt to rapid changes taking place
in both society and the market as it provides for the social values
of safety, security, fairness and efficiency to promote a more
sustainable world where everyone has the chance to reach their full
potential. For more information, visit NEC at https://www.nec.com
and NEC’s AI Drug Development Business at
https://www.nec.com/en/global/solutions/ai-drug/.
About BostonGene Corporation
BostonGene has a mission to provide transformative, AI-integrated
molecular analytics and biomarker discovery for precision matching
of therapies to improve the lives of patients living with cancer
and other immune-related diseases. BostonGene’s service model
provides customized client solutions using a multi-omic approach
prioritized for real-world impact, including optimized
standard-of-care therapies, accelerated research and
cost-effective, measurable results. BostonGene’s tests reveal
key drivers of each patient’s unique disease profile, including an
in-depth profile of the immune microenvironment, actionable
mutations, biomarkers of response to diverse therapies, and
recommended therapies. Through these comprehensive analyses,
BostonGene’s tests generate a personalized roadmap for therapeutic
decision-making for each patient. For more information, visit
BostonGene at http://www.BostonGene.com.
Contacts:
Transgene
Lucie
Larguier
VP, Corporate Communications & IR
+33 (0)3 88 27 91 04
investorrelations@transgene.fr |
Media: MEDiSTRAVA Consulting
Frazer Hall/Sylvie Berrebi
+44 (0)203 928 6900
transgene@medistrava.com |
NEC
Joseph Jasper
+81-3-3798-6511
j-jasper@nec.com
BostonGene
Erin O’Reilly
+1-617-283-2285
Erin.Oreilly@BostonGene.com
Transgene
disclaimer
This press release contains forward-looking statements, which are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. The
occurrence of any of these risks could have a significant negative
outcome for the Company’s activities, perspectives, financial
situation, results, regulatory authorities’ agreement with
development phases, and development. The Company’s ability to
commercialize its products depends on but is not limited to the
following factors: positive pre-clinical data may not be predictive
of human clinical results, the success of clinical studies, the
ability to obtain financing and/or partnerships for product
manufacturing, development and commercialization, and marketing
approval by government regulatory authorities. For a discussion of
risks and uncertainties which could cause the Company’s actual
results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please
refer to the Risk Factors (“Facteurs de Risque”) section of the
Universal Registration Document, available on the AMF website
(http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
- 20240305_Transgene_NECBio_BostonGene_Press_Release_EN
Transgene (LSE:0OCQ)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Transgene (LSE:0OCQ)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024